An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1. The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage.

The present invention relates to topical compositions comprising 10-hydroxystearic acid or a salt thereof and at least one nonionic emulsifier. The present invention also relates to a method to retard or inhibit the re-crystallisation of 10-hydroxystearic acid or a salt thereof in a topical composition, said method comprising formulating 10-hydroxystearic acid or a salt thereof in the presence of at least one nonionic emulsifier.

An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1. The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage.

Provided is a water-in-oil type cosmetic including: an oil agent having a melting point of 20 C. or lower; a silicone gel; a modified silicone surfactant having a hydrophile-lipophile balance value of less than 6; inorganic particles of at least one selected from the group consisting of titanium oxide, iron oxide, and mica; water; and a co-emulsifier, in which the oil agent having a melting point of 20 C. or lower contains 60% by mass or greater of silicone oil, a content of the modified silicone surfactant having a hydrophile-lipophile balance value of less than 6 is greater than 0.1% by mass and less than 1% by mass with respect to a total amount of the water-in-oil type cosmetic, and the inorganic particles of at least one selected from the group consisting of titanium oxide, iron oxide, and mica are contained in an oil phase.

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

The subject-matter of the present invention is an anhydrous cosmetic composition comprising, in a physiologically acceptable medium: at least one nonionic surfactant, at least one anionic surfactant, at least 25% of at least one filler. The article is partially or completely soluble in water and it constitutes a foaming product used for cleansing the skin and hair and/or removing makeup from the skin and/or as scrubbing product.

Disclosed herein are compounds for use in lightening skin, treating uneven skin pigmentation and/or improving the appearance of aging skin, as well as methods utilizing the compounds, and anti-aging compositions comprising the compounds and a pharmaceutically acceptable carrier. The compounds have the general Formula I:

##STR00001## or a pharmaceutically acceptable salt thereof, wherein the dashed line, X, Y, Z, Ra-Rd, and R.sub.1-R.sub.3 are as defined herein.

Compositions are disclosed herein, as well as methods and uses utilizing the compositions for improving the appearance of aging skin, lightening skin, treating uneven skin pigmentation and/or treating a sexual disorder. The compositions comprise a compound of the general Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the dashed line, X, Y, Z, Ra-Rd, and R.sub.1-R.sub.5 are as defined herein, and a carrier suitable for topical administration on skin, being in a form of a water-in-oil emulsion, the emulsion comprising: propylene glycol, phosphatidyl choline, lauroyl macrogolglycerides, macrogolglycerol stearate, ethanol, caprylocaproyl macrogolglycerides, propylene glycol monolaurate and water, in proportions described herein.

A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water,

##STR00001##

wherein R.sup.1 is a C.sub.9-23 aliphatic group; R.sup.2 is a hydrogen atom or a C.sub.1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R.sup.3 is a (CH.sub.2).sub.nX group; n is a number of 1 to 4; and X is amino group, guanidino group, CONH.sub.2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.

Biodegradable surfactants are described, in which an amphiphilic heteroatom containing hydrocarbon optionally comprising at least one counterion (Z), and related compositions, methods and systems. Biodegradable surfactant described herein has an aHLB value in accordance with equation (1): aHLB=20*Gh/(GhGt) (1) wherein Gh is the Group Number of a hydrophilic head portion of the biodegradable surfactant optionally comprising the at least one counterion (Z), and Gt is the Group Number of a hydrophobic tail portion of the biodegradable surfactant. A biodegradable surfactant in the sense of the disclosure can be tuned to a set hydrophilic-lipophilic balance (aHLB) by selectively modifying at least one tuning moiety of the biodegradable surfactants to provide tuned biodegradable surfactants having an increase or decrease in their adjusted hydrophilic-lipophilic balance (aHLB).